BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Bio-Rad Laboratories, Inc. (BIO)'s New iTaq™ Universal Supermixes Offer Robust Performance on Any Real-Time PCR Instrument


5/14/2012 11:47:35 AM

HERCULES, CA — May 14, 2012 — Bio-Rad Laboratories, Inc. announced today that it has introduced two iTaq Universal supermixes that are compatible with any real-time PCR instrument. These products deliver robust performance and enable users to obtain high-quality data across all real-time quantitative PCR (qPCR) applications,.

The two new iTaq Universal supermixes include the iTaq Universal SYBR® Green supermix and the iTaq Universal Probes supermix, both of which are 2x concentrated, ready-to-use reaction master mixes. Both supermixes are made with a proprietary optimized buffer formulation for maximum sensitivity, efficiency and reproducibility.

The term “Universal” refers to the broad instrument compatibility and the ability to tolerate a broad range of reaction and protocol conditions. The iTaq Unversial supermixes, which contain a blend of multiple passive reference dyes, are particularly useful for researchers using real-time PCR instruments that require ROX fluorescent dyes. Researchers will now be able to use a single supermix, eliminating the need to change reagents between experiments and instruments.

The SYBR® Green supermix is optimized for dye-based qPCR and contains SYBR® Green I dye whereas the Probes supermix is formulated for probe-based qPCR (simplex or duplex).

Key benefits of the iTaq Universal supermixes include:

- Broad dynamic range and sensitivity — offers accurate and sensitive detection of a broad range of targets in gene expression analysis and other real time applications

- Optimized buffer formulation — provides efficient amplification of genomic DNA templates and difficult amplicons

- Overcomes challenging duplex qPCR — enables detection of two gene targets, even with a great differential in copy number, in one reaction

- Antibody-mediated hot-start DNA polymerase — gives instant and complete polymerase activation in 30 seconds

Visit www.bio-rad.com/supermixes for more information about the iTaq Universal supermixes.

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The Company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 100,000 research and industry customers worldwide through its global network of operations. The company employs over 7,100 people globally and had revenues exceeding $2 billion in 2011. For more information, visit www.bio-rad.com.

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, “believe,” “expect,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the “Risk Factors” in the Company’s public reports filed with the Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.

For more information contact:

Richard Kurtz

Bio-Rad

510-741-5638

Richard_Kurtz@bio-rad.com

Ken Li

Chempetitive Group

312-997-2436 x 112

kli@chempetitive.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES